Comparative Pharmacology
Head-to-head clinical analysis: GLIADEL versus VALCHLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLIADEL versus VALCHLOR.
GLIADEL vs VALCHLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GLIADEL (carmustine implant) is a biodegradable wafer that delivers carmustine, a nitrosourea alkylating agent, directly into the tumor resection cavity. Carmustine alkylates DNA and RNA, leading to cross-linking and inhibition of DNA replication, ultimately causing cell death. It is cell cycle phase nonspecific.
Valchlor (mechlorethamine) is a nitrogen mustard alkylating agent that forms cross-links between DNA strands, leading to inhibition of DNA replication and transcription, and inducing apoptosis in rapidly dividing cells.
Gliadel (carmustine) implant is administered intraoperatively as 8 wafers, each containing 7.7 mg carmustine, placed in the resection cavity after tumor debulking. Maximum dose is 61.6 mg (8 wafers).
Topical: Apply 0.016% mechlorethamine gel to affected areas once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1.3 hours for the active dianhydrogalactitol metabolite. Clinical context: short half-life supports local interstitial delivery with minimal systemic accumulation.
The terminal elimination half-life is approximately 24 hours after topical application, supporting daily dosing. Systemic half-life may be prolonged in patients with hepatic impairment.
Primarily renal (60-70% as unchanged drug and metabolites) and biliary/fecal (15-20%). Approximately 10-15% is eliminated via exhaled air as CO2.
Following topical application, VALCHLOR (mechlorethamine) is systemically absorbed; approximately <10% is excreted unchanged in urine. The majority of the dose is eliminated via metabolism and biliary/fecal routes, with ~50% of a systemic dose recovered in feces as metabolites.
Category C
Category C
Alkylating Agent
Alkylating Agent